The National Agency for Food and Drug Administration and Control (NAFDAC), has distanced itself from a PAXHERBAL claim that it has developed a drug for the treatment of COVID-19.
We had earlier reported that Pax Herbal Clinic and Research Laboratories, Ewu, in Edo State managed by the Oblates of St Benedictine’s Catholic Monks announced the development of a herbal medicine, “CVD PLUS” for the coronavirus cure.
It had issued an advertorial to the public, signed by Fr Anslem Adodo OSB, claiming the research for the PAX CVD PLUS is a joint effort of experts from two notable Federal Universities, University of Lagos and University of Benin, a tertiary health institution, Irrua Specialist Teaching Hospital, Edo State and experts sent by Prof. Tunde Salako and Prof. Catherine Adeyeye.
The advertorial was also alleged to have claimed that NAFDAC Director General, Prof. Mojisola Adeyeye has appointed experts to work with Paxherbal on what the laboratory described as a special project.
Meanwhile, in a statement NAFDAC DG refuted the collaboration, adding that the laboratory was yet to be registered with the agency or listed for the treatment of COVID-19.
Read the full NAFDAC statement below:
“The attention of the Agency has been drawn to an advertorial from Paxherbal clinic and research laboratories, NAFDAC wishes to inform the public that PAX CVD PLUS has not been registered nor listed for treatment of COVID-19.
“To set the records straight, at no time did the DG or anyone in the agency appoint any expert or staff to work with Paxherbal on any project.
“The company wrote a letter to NAFDAC informing the agency about their development of an antiviral plant based drug with potential to treat COVID-19 and an invitation to join their research team.
“The Agency politely declined since as a regulator of clinical trials, participation would be a conflict of interest.
“However, we encouraged them to carry out clinical trials which should be under strict supervision of the agency to establish efficacy of their product.
“However, the clinical trial has not taken place.”
According to the agency, it was unfortunate that PAXHERBAL have made claims that were not backed up by facts and this response was intended to correct the erroneous impression created by the advertorial.